3 assets in Acute Basophilic Leukemia

Therapeutic assets addressing Acute Basophilic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Basophilic Leukemia	National Cancer Institute (NCI)	P3	BBB (74)
Daunomycin Acute Basophilic Leukemia	National Cancer Institute (NCI)	P3	BB (70)
Decitabine Acute Basophilic Leukemia	National Cancer Institute (NCI)	P2	CCC (53)